Nocturne Acquisition Corp

Nocturne Acquisition Corp. is a blank check formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on October 28, 2020 and is headquartered in Wilmington, DE.

Nocturne Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on October 28, 2020 and is headquartered in Wilmington, DE.

Nocturne Acquisition Corp - Unit

Transaction Expected to Accelerate the Research and Advancement of Cognos' Proprietary and Innovative Implantable Drug Delivery Pump to Improve Outcomes for Treatment of Brain Cancers and Other Neurological Diseases WILMINGTON, DE / ACCESSWIRE / August 16, 2023 / Nocturne Acquisition Corporation (NASDAQ:MBTC)(NASDAQ:MBTCU)(NASDAQ:MBTCR) (the "Company", "MBTC" or "Nocturne"), today announced the submission via Edgar, the U.S. Securities and Exchange Commission's ("SEC") online portal, for filing of a registration statement on Form S-4 (the "Registration Statement") with the SEC, which includes a preliminary proxy statement/prospectus in connection with the proposed business combination (the "Business Combination") with Cognos Therapeutics, Inc. ("Cognos"), a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions (such as Alzheimer's and Parkinson's disease), epilepsy, and stroke. The Registration Statement contains a preliminary proxy statement/prospectus in connection with the previously announced Business Combination between Nocturne and Cognos.

Nocturne Acquisition Corporation Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Cognos

Cognos Therapeutics is a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions (such as Alzheimer's and Parkinson's disease), epilepsy, and stroke. Cognos' lead product candidate is the SINNAISTM Implantable Smart Pump, believed to be the world's first implantable device under development for the metronomic delivery of therapeutics for neurological diseases, including brain cancer.

News for Nocturne Acquisition Corp Stock (MBTCR)